Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 1991

A plane has to be going pretty fast for a mere raindrop to crack its windshield, but it can happen. Now, new models of the physics behind the improbable feat may just help doctors crack kidney stones to pieces.

When supersonic jets were first being developed for commercial use in the 1960s, researchers discovered a curious phenomenon that sometimes occurs on test flights through rainforests. Even though raindrops weigh almost nothing, they are capable of creating ring-shaped cracks in the jets’ substantial windshields.

Although scientists initially had difficulty explaining this curiosity, Professors Frank Philip Bowden and John Field of the University of Cambridge eventually recognized as the culprits. Because surface waves spread in only two dimensions, they pack a much more powerful punch than their three-dimensional counterparts. Certain details of the phenomenon, however, have remained poorly understood due to a lack of mathematics to describe it and experimental setups to validate proposed models.

Read more | >

Now researchers have turned to yeast to do something more improbable: manufacturing the cannabis compounds CBD and THC. By loading brewer’s yeast with genes from the cannabis plant, they’ve turned the miracle microbes into cannabinoid factories. It’s a clever scheme in a larger movement to methodically pick apart and recreate marijuana’s many compounds, to better understand the plant’s true potential.

Yeast gives us beer and bread. Now researchers have engineered it to do something more improbable: manufacturing the cannabis compounds CBD and THC.

Read more | >

Holon-based cancer immunotherapy company Compugen disclosed encouraging preliminary results on Tuesday from its Phase 1 clinical trial for an antibody acting against a novel cancer drug target (PVRIG) in patients with advanced solid tumors.

The Nasdaq and Tel Aviv-listed company, a pioneer in predictive drug target discovery, has developed innovative computational discovery platforms to identify new drug targets and subsequently produce first-in-class therapeutics. The clinical trial of the anti-PVRIG antibody, called COM701, aimed to assess the safety of escalating doses of the therapy in patients with advanced solid tumors, but also demonstrated initial signals of anti-tumor activity in the heavily pre-treated patient population enrolled in the study.

“We are encouraged by the emerging safety profile and initial signals of anti-tumor activity of COM701,” said Compugen president and CEO Dr. Anat Cohen-Dayan.

Read more | >

“…consider Robert Nozick’s thought-experiment in conjunction with Felipe De Brigard’s inverse experience machine argument: “If you like it, does it matter if it’s real?”

Does Nozick’s experience machine prove anything?

Perhaps consider Robert Nozick’s thought-experiment in conjunction with Felipe De Brigard’s inverse experience machine argument: “If you like it, does it matter if it’s real?”

Continue reading “David Pearce — Experience Machines and Hedonic Treadmills” | >

A new study from the Johns Hopkins University School of Medicine shows that selectively removing senescent cells—cells that no longer divide—from brains with a form of Alzheimer’s disease can reduce brain damage and inflammation and slow the pace of cognitive decline. These findings, say researchers, add to evidence that senescent cells contribute to the damage caused by Alzheimer’s disease.

“Our results show that eliminating these cells may be a viable route to treat Alzheimer’s disease in humans,” says Mark Mattson, a professor of neuroscience at the School of Medicine and a senior investigator in the Laboratory of Neurosciences at the National Institute on Aging.

A report on the work was published April 1 in Nature Neuroscience.

Read more | >

Focused ultrasound (FUS) can be used to help drugs pass from the bloodstream into the brain, but the technique’s effectiveness depends on the ultrasound pressure and the size of the drug molecules. Michael Valdez and colleagues at the University of Arizona measured how thoroughly differently sized molecules diffused into mouse brains under a range of ultrasound intensities, and found that the largest molecules could not be delivered under any safe FUS regime. The results set a limit on the types of drugs that might one day be used to treat neurological conditions like Alzheimer’s and Parkinson’s disease (Ultrasound Med. Biol. 10.1016/j.ultrasmedbio.2019.08.024).

Usually, the brain is isolated from substances circulating in the bloodstream by the blood–brain barrier (BBB), a semipermeable layer of cells that permits only certain molecules to pass. This restricts the range of drugs that can be used in the brain to small, hydrophobic molecules (such as alcohol and caffeine), other small drugs like psychotropics and some antibiotics. Extending that range would open the door to new therapeutic possibilities, says Theodore Trouard, who led the team. “The ability to temporarily and safely open the BBB to allow drugs into the brain would help address a number of neurological diseases for which there is currently no effective treatment.”

Previous research has shown that such opening can be achieved by focusing an ultrasound beam in the brain while gas microbubbles circulate in the blood. The microbubbles – perfluorocarbon-filled lipid shells about 1 µm across – are inert while they move around the body, but rapidly expand and contract in the local pressure fluctuations caused by the ultrasound field. Mechanical forces exerted by this phenomenon create temporary gaps in the layer of cells that make up the BBB, giving larger molecules a chance to breach the brain’s defences.

Read more | >

Authorities in China have approved a drug for the treatment of Alzheimer’s disease, the first new medicine with the potential to treat the cognitive disorder in 17 years.

The seaweed-based drug, called Oligomannate, can be used for the treatment of mild to moderate Alzheimer’s, according to a statement from China’s drug safety agency. The approval is conditional however, meaning that while it can go on sale during additional clinical trials, it will be strictly monitored and could be withdrawn should any safety issues arise.

In September, the team behind the new drug, led by Geng Meiyu at the Shanghai Institute of Materia Medica under the Chinese Academy of Sciences, said they were inspired to look into seaweed due to the relatively low incidence of Alzheimer’s among people who consume it regularly.

Read more | >

When the first smartphones arrived, few people understood how they would change our reality. Today, our internet-connected mobile device maps our travel, manages our finances, delivers our dinner, and connects us to every corner of human knowledge. In less than a generation, it has become almost an extension of our central nervous system — so indispensable that we can’t imagine leaving home without it to guide us.

We are about to embark on another journey even more important to every individual and to human society. We are entering the age of genomics, an amazing future that will dramatically improve the health outcomes of people across the planet. Soon, we won’t be able to imagine a time when we left home without knowledge of our genome to guide us.

But this future isn’t a generation away. As early as 2020, I believe we will be living in a world where software uses knowledge of our personal genome to guide us, like a health GPS, toward choices that are appropriate for us as individuals. From the foods we choose to eat to the medicines we take to prevent or cure disease, from helping us avoid exposure to environmental risks to eradicating thousands of genetic diseases, genomics will reveal such immense possibilities that it will feel as if we can see and hear for the first time.

Read more | >